Intervention Helps Prostate Cancer Patients Make Better Choices

(MedPage Today) -- Patient preference assessment tool aligns with pros and cons of prostate cancer therapies
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news

Related Links:

Ginevra Doglioni1,2†, Sweta Parik1,2† and Sarah-Maria Fendt1,2* 1Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium 2Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, KU Leuven and Leuven Cancer Institute, Leuven, Belgium Metastasis formation is the leading cause of death in cancer patients. Thus, understanding and targeting this process is an unmet need. Crucial steps during the establishment of metastases include the (pre)metastatic niche formation. This process relies on the interaction of th...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, we showed hypermethylation of CpGs as a novel mechanism of action for DNMTi agents and identified 638 hypermethylated molecular targets (CpGs) common to decitabine and azacytidine therapy. These novel results suggest that hypermethylation of CpGs should be considered when predicting the DNMTi responses and side effects in cancer patients. Introduction DNA methyltransferase inhibitors (DNMTi) are widely used as chemical tools for hypomethylating the genome, with an aim to understand the role of DNA methylation in multiple processes (e.g., X-chromosome inactivation and DNA imprinting) and as an anti-ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
When a prostate cancer staging exam is needed, clinicians at one Australian...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Gallium-labeled PET tracer could advance cancer detection SNMMI: Early prostate cancer therapy extends lives
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
When a prostate cancer staging exam is needed, clinicians at one Australian...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Gallium-labeled PET tracer could advance cancer detection SNMMI: Early prostate cancer therapy extends lives
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human diseases. FI...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Markus Hartl* and Rainer Schneider Center of Molecular Biosciences (CMBI), Institute of Biochemistry, University of Innsbruck, Innsbruck, Austria The neuronal proteins GAP43 (neuromodulin), MARCKS, and BASP1 are highly expressed in the growth cones of nerve cells where they are involved in signal transmission and cytoskeleton organization. Although their primary structures are unrelated, these signaling proteins share several structural properties like fatty acid modification, and the presence of cationic effector domains. GAP43, MARCKS, and BASP1 bind to cell membrane phospholipids, a process reversibly regulate...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Lei Liu1,2,3, Lin Zhang1,2, Shuo Zhao4, Xu-Yang Zhao1,2, Peng-Xiang Min4, Ya-Dong Ma4, Yue-Yuan Wang4, Yan Chen1,2, Si-Jie Tang4, Yu-Jie Zhang2,4, Jun Du2,4 and Luo Gu2,4* 1Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, China 2Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China 3Department of Physiology, Xuzhou Medical University, Xuzhou, China 4Department of Physiology, Nanjing Medical University, Nanjing, China Tumor cell migration is a critical step...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: Mathematical models can integrate evolutionary dynamics into multidrug cancer clinical trials. This has the potential to improve outcomes and to develop clinical trials in which these mathematical models are also used to estimate the mechanism(s) of treatment failure and explore alternative strategies to improve outcomes in future trials. PMID: 30992299 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Leptomeningeal carcinomatosis (LC) is a rare leptomeningeal spread of diffusely metastatic tumors. It occurs more commonly with hematologic tumors, less commonly with solid tumors, and is exceedingly rare in prostate cancer. Due to its scarcity, it has traditionally been difficult to diagnose LC but advancement of MRI has helped considerably. However, even with technological improvements, pre-mortem diagnosis of LC remains difficult and controversial. Our case is a 71-year-old male with prostate cancer with bone metastases who presented to our facility with altered mental status (AMS), lower extremity weakness, and worseni...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Authors: Li N, Xie X, Hu Y, He H, Fu X, Fang T, Li C Abstract Prostate cancer (PCa) is a leading cause of cancer-related deaths among men. The anthracycline doxorubicin (DOX) is used for the treatment of this disease, but its considerable side effects and non-selectivity are major drawbacks. Simvastatin (Sim), a lipid-lowering agent, holds great promise as a cancer therapeutic, and thus could be used in combination with DOX. Targeted drug-loaded nano-carriers with antibodies for receptors that are overexpressed on tumor cells are promising strategies for decreasing toxicity to normal tissues and enhancing the effic...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Primary Care | Prostate Cancer